Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
The reported figure is also wider than the year-ago quarter's loss of 46 cents per share. Currently, Immunovant does not have any approved product in its portfolio. As a result, it has yet to generate revenues. Quarter in Detail Research and development (R&D) expenses totaled $66.1 million, up 27% from the year-ago quarter's reported figure. The year-over-year rise can be attributed to increased operational costs and R&D activities for IMVT-1402 and batoclimab programs. General and administrative expenses amounted to $14.8 million, up 19% on a year-over-year basis. The rise was primarily due to an increase in personnel-related expenses and legal and other professional fees. As of Mar 31, 2024, Immunovant had a cash balance of $635 million compared with $691 million as of Dec 31, 2023. The company's stock lost 5.3% in the after-market hours as the investors were disappointed by the wider-than-expected fiscal fourth-quarter loss. Year to date, shares of Immunovant have plung
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $46.00. They now have an "outperform" rating on the stock.MarketBeat
- Roivant Sciences: Executing On Huge Buyback Program With More To Come [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
IMVT
Earnings
- 5/29/24 - Miss
IMVT
Sec Filings
- 6/26/24 - Form DEFA14A
- 6/26/24 - Form DEF
- 5/29/24 - Form 10-K
- IMVT's page on the SEC website